logo
North Carolina A&T State University provides biotechnology resources for teachers in the Triad

North Carolina A&T State University provides biotechnology resources for teachers in the Triad

Yahoo14-07-2025
GREENSBORO, N.C. (WGHP) — It's called the Amgen Biotech Experience and for a number of teachers across the Piedmont, it could be the key to helping their students learn all about biotechnology. They have come to North Carolina A&T State University for two days of intensive training on how to better help their students learn all about bio-tech and how to use it in their classroom lessons. That includes online learning, resources and contacts that show how the procedures they are learning now are applied in real life.
According to North Carolina A&T Associate Professor of Biology Dr. Misty Thomas, 'We then split half of our time in the actual lab. So, we ran all our teachers through all the protocols, all the experiments that they would be doing with their students. And we also make sure that in the lab, they have all the exact materials they're going to have in their classroom. So that way then they've touched everything. They've played with everything. They've gone through all of the labs, so they're better prepared to then take it into their classroom.'
The university has also put together lab kits with everything the teachers will need to conduct experiments in their own classrooms.
'They can borrow the kit for three weeks, take it with them, do all their labs, and they give it back to us. We turn the kit over, and then we give it to a new teacher. So they're constantly going out week after week,' says Dr. Thomas.
For the teachers, it is an incredible resource. This will be the third year Kimberly Griffis has used the program in her classroom. She says her students love it.
'The great thing about it is they get excited about science,' says Griffis. 'You have scholars who might not be so excited about it at first. But when you implement hands-on activities in the classroom, they get so excited, and they look forward to coming to school every day because they don't know what's going to happen in the classroom with science. And so when they're able to pretend to be a forensic science or crime scene investigator or just a scientist or a lab technician, they get so excited they learn how to collaborate with one another and work together in teams.'
She says the lab kits are so versatile, they can be incorporated for use in many different subjects.
According to Griffis, 'It's amazing because you're even with the pop heading when we do the DNA activity, you could do multiplication with it. You can do addition with it. So, you can incorporate math and all that. We've even used this program to do a crime scene unit at our school, where we set up the crime scene and they had to figure out who committed the crime. We involved our community resources, such as the Greensboro CSI police, you know, with the Police Department. They came to our school, they talked about how they solve crimes and they did the fingerprinting and stuff.'
The best part of all, according to NC A&T Biology Professor Dr. Joseph Lewis Graves, Jr., the program and training is entirely free.
'We provide them not only the professional equipment, but all of the training and all the supplies are paid for through the Amgen award. So none of this comes out of their pocket and we can reimburse them for their time being trained to be able to deliver this material to their kids,' he said.
Dr. Graves sees this partnership only growing with time.
'What we want is for these kids, when they go through their training in the public schools, we want them to consider coming to us as students,' he said. 'So, we're engaged in North Carolina. We want to keep North Carolina kids in North Carolina schools and we want people to understand that North Carolina A&T is one of the research powerhouses in the state of North Carolina.'
Growing promising scientists from kindergarten on, one science project at a time.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Yahoo

timea day ago

  • Yahoo

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Fourth Cohort Receiving 30x Initial Dose with No Dose-Limiting Toxicities Observed to Date SAN JOSE, Calif., Aug. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient in the fourth dose cohort has been treated in the ongoing Phase 1 clinical trial evaluating the Company's novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center ("Moffitt"). Patients in the fourth cohort are receiving a dose of three million CAR-positive cells per kilogram of body weight—representing a 30-fold increase over the initial dose level. To date, no dose-limiting toxicities (DLTs) have been observed in the fourth cohort. Anixa's proprietary CAR-T program targets the follicle-stimulating hormone receptor (FSHR), which preclinical research indicates is selectively expressed on ovarian cells, tumor vasculature, and certain cancer cells—but not in healthy tissue. The ongoing first-in-human clinical trial (NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior lines of therapy. The Phase 1 study is designed to evaluate safety, determine the maximum tolerated dose, and monitor initial signals of clinical activity. "Our therapy continues to demonstrate a favorable safety profile, even at significantly higher cell doses," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "While this study is primarily designed to assess safety, we remain encouraged by early indications of potential efficacy as the trial progresses." Anixa's CAR-T technology was invented by Jose R. Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine. The ongoing clinical trial is being conducted at Moffitt under the direction of Dr. Robert Wenham, Chair of the Gynecologic Oncology Program. Anixa holds an exclusive worldwide license to the FSHR-targeting CAR-T technology from The Wistar Institute. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit or follow Anixa on LinkedIn, X, Facebook and YouTube. Forward-Looking StatementsStatements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact:Mike CatelaniPresident, COO & CFOmcatelani@ View original content to download multimedia: SOURCE Anixa Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Youthful Immune System in Old Age Can Apparently Be Harmful
Youthful Immune System in Old Age Can Apparently Be Harmful

Yahoo

time2 days ago

  • Yahoo

Youthful Immune System in Old Age Can Apparently Be Harmful

Immune defenses that function in old age as they did in youth are considered desirable. However, a recent study shows that a youthful immune system in older age can also cause harm. Follow the FITBOOK channel on WhatsApp now! As part of the natural aging process, the human immune system weakens over the years.1 One reason for increased susceptibility to infections in old age is that fewer new T-cells are produced, as the thymus—the maturation organ for T-cells—shrinks. T-cells recognize and destroy harmful cells in the body and activate other parts of the immune system. Because the immune system weakens with age, people with an active immune system seem to have an advantage. But: This supposed immune youthfulness can apparently also be harmful. Also interesting: Certain diets could cripple the immune system Details of the Study A research team from the U.S. Mayo Clinic found, after evaluating health records of about 22 million people, that many autoimmune diseases only appear in older age. At the same time, it is known that general immune defense weakens with age.2 From this paradox, the researchers concluded that the immune system in older age is not just still active but sometimes possibly too active. In autoimmune diseases, a malfunction of the immune system is known to occur, leading the body to attack its own tissue. Researchers Found Immune Cells in Diseased Tissue of Giant Cell Arteritis Patients In the next step, the scientists examined aortic sections from more than 100 patients over 50 years old, who are being treated for giant cell arteritis at the U.S. Mayo Clinic. This is a rarer, inflammatory autoimmune disease of the large and medium arteries, often affecting the cranial arteries and aorta. The Mayo Clinic is globally renowned for its expertise in complex diseases, including giant cell arteritis (GCA).3 The researchers found an increased presence of specialized immune cells, known as stem cell-like T-cells, in the diseased tissue of the patients. To recap: The previously mentioned T-cells are normally responsible for fighting infections as part of the immune system. These special T-cells behave similarly to T-cells in young organisms, as they can renew themselves and continuously produce new defense cells. However, in the presence of giant cell arteritis, this seemingly beneficial effect appears to be misguided. Instead of protecting the body from invaders, these cells continuously supply new T-cells that attack the blood vessels of those affected. Their efficiency thus causes significant damage. How a Youthful Immune System Attacks Its Own Cells As people age, more new, unusual protein forms accumulate in the body, the study authors write: so-called neoantigens. The immune system has not yet developed tolerance to these proteins. 'This is likely to inevitably lead to an increase in autoimmune diseases in old age,' the study continues. Normally, the immune system prevents these neoantigens from attacking its own cells. However, with age, these control mechanisms can be disrupted—a possible explanation for why autoimmune diseases occur more frequently in old age. The study's results suggest that autoimmune diseases in old age are not solely a result of weaker defenses. In summary, a combination of 'youthful' T-cells and an increasing number of new antigens seems to lead to the immune system being unable to stop certain inflammations in old age. Part of the immune system remains overly efficient, and this can be harmful to the aging body. Significance of the Study and Limitations The observations could offer new perspectives for medical practice—at least if the findings are confirmed in further studies. The research team plans to develop diagnostic tests that could potentially predict autoimmune diseases later in life based on the high activity of immune stem cells in currently healthy individuals. For study author Dr. Jörg Goronzy, these findings are already significant. 'Contrary to popular belief, an immune system that ages with the body does have advantages,' he explains in a press release.3 He suggests that moderate aging of the immune system can be protective, as it dampens the response to one's own cells. It should be noted that the study is based on existing studies. No new experiments were conducted; rather, existing data were interpreted. This limitation may slightly affect the reliability of the results. Additionally, only tissue from giant cell arteritis patients was analyzed. Whether the observations can be applied to other autoimmune pathologies remains unclear—likewise, how the specific, stem cell-like T-cells that are beneficial for tissue repair differ from those that contribute to autoimmune pathology in older patients. FITBOOK has reached out to the authors with these and other questions. A response is still pending. The post Youthful Immune System in Old Age Can Apparently Be Harmful appeared first on FITBOOK.

Musk's Starlink suffers apparent outage as SpaceX launches more satellites
Musk's Starlink suffers apparent outage as SpaceX launches more satellites

CNBC

time2 days ago

  • CNBC

Musk's Starlink suffers apparent outage as SpaceX launches more satellites

Satellite internet service Starlink, which is owned and operated by Elon Musk's SpaceX, appeared to suffer a brief network outage on Monday, with thousands of reports of service interruptions on Downdetector, a site that logs tech issues. The outage marked the second in two weeks for Starlink. SpaceX did not immediately respond to a request for comment. The network's July 24 outage lasted for several hours, with SpaceX Vice President of Starlink Engineering Michael Nicolls blaming the matter on "failure of key internal software services that operate the core network" behind Starlink. That outage followed the launch of T-Mobile's Starlink-powered satellite service, a direct-to-cell-phone service created to keep smartphone users connected "in places no carrier towers can reach," according to T-Mobile's website. SpaceX provides Starlink internet service to more than six million users across 140 countries, according to the company's website, though churn and subscriber rates are not publicly reported by the company. The SpaceX Starlink constellation is far larger than any competitor. It currently features over 7,000 operational broadband satellites, according to research by astronomer Jonathan McDowell. On Monday, Musk's SpaceX successfully launched another group of satellites to add to its Starlink constellation from the Vandenberg Space Force Base in Southern California. SpaceX is currently aiming to increase the number of launches and landings from Vandenberg from 50 to about 100 annually. On Thursday last week, the California Coastal Commission voted unanimously to oppose the U.S. Space Force application to conduct that higher volume of SpaceX launches there. The Commission has said that SpaceX and Space Force officials have failed to properly evaluate and report on potential impacts of increased launches on neighboring towns, and local wildlife, among other issues. President Donald Trump recently signed an executive order seeking to ease environmental regulations seen by Musk, and others, as hampering commercial space operations.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store